Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Trump and Lula Discuss Trade, Sanctions, and Security in “Productive” Phone Call 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Australia Progresses AUKUS Review as U.S. Affirms Strong Support 
Trump Pardons Former Honduran President Juan Orlando Hernández in Controversial Move 
Trump Administration Plans Major Rollback of Biden-Era Fuel Economy Standards 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
Putin Concludes High-Level Talks With Trump Envoy on Ending Ukraine Conflict 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on ensuring vaccine safety and efficacy, said it expects to complete its review by early December. The move follows a decision by a federal advisory committee under the Centers for Disease Control and Prevention (CDC) to delay a vote on whether to postpone the first hepatitis B dose for newborns of mothers who test negative for the virus.
The review will analyze decades of scientific research on the safety, effectiveness, and public health outcomes of administering the hepatitis B vaccine within the first 24 hours of life. It will also evaluate the potential risks of delaying the vaccine, including missed opportunities for immunization due to incomplete maternal screening or lack of follow-up.
Currently, the CDC and World Health Organization recommend that all newborns receive the hepatitis B vaccine shortly after birth to prevent mother-to-child transmission. Data show that infants infected at birth or within their first year face up to a 90% chance of developing chronic hepatitis B, which can lead to cirrhosis or liver cancer later in life.
The discussion has gained political attention after President Donald Trump questioned the necessity of giving the vaccine at birth, suggesting instead that it could be delayed until age 12, citing its transmission through sexual contact. However, health experts emphasize that perinatal infection remains a significant transmission route.
Since the introduction of widespread vaccination, hepatitis B infection rates in the United States have dropped by nearly 90%, from about 9.6 per 100,000 people before the vaccine program began to around one per 100,000 in 2018. Currently, six hepatitis vaccines are approved for use in the U.S., continuing to play a vital role in reducing the disease’s prevalence and protecting future generations.
